Journal Watch · Journal of Medicinal Chemistry · 2026
Synthesis, Biological Evaluation, and Biodistribution of Xinyne, a Novel Quinazoline-carbazole N-methylamine Anticancer Agent Used in Mice Xenograft Models.
Finally, the antitumor efficacy of Xinyne was confirmed in a murine breast cancer model.
TL;DR
Finally, the antitumor efficacy of Xinyne was confirmed in a murine breast cancer model.
Key findings
- A biodistribution study demonstrated preferential accumulation of [14C]-Xinyne in the liver and the small intestine, with larger elimination through feces.
- Finally, the antitumor efficacy of Xinyne was confirmed in a murine breast cancer model.
What they did
To investigate its in vivo behavior, radiolabeled [14C]-Xinyne was prepared using [14C]-KCN. Pharmacokinetic analysis revealed significant sex-based differences: males showed faster absorption and more efficient elimination, whereas females exhibited broader tissue distribution and slower clearance.
Full abstract (original)
Background: Xinyne, a diaryl-N-methylamine analogue of isoCombretastatin A-4 was synthesized via a late-stage Cl-exchange using KCN. Xinyne exhibited potent antiproliferative activity at nanomolar concentrations against various human cancer cell lines, inhibited tubulin polymerization, induced apoptosis, and induced G2/M phase cell cycle arrest in 4T1 cells.
What they did: To investigate its in vivo behavior, radiolabeled [14C]-Xinyne was prepared using [14C]-KCN. Pharmacokinetic analysis revealed significant sex-based differences: males showed faster absorption and more efficient elimination, whereas females exhibited broader tissue distribution and slower clearance.
Results & conclusions: A biodistribution study demonstrated preferential accumulation of [14C]-Xinyne in the liver and the small intestine, with larger elimination through feces. Finally, the antitumor efficacy of Xinyne was confirmed in a murine breast cancer model.
Abstract © the authors / Journal of Medicinal Chemistry (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1021/acs.jmedchem.6c00338 · PubMed 42720493.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Journal of Medicinal Chemistry for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Journal of Medicinal Chemistry study find?
Finally, the antitumor efficacy of Xinyne was confirmed in a murine breast cancer model.
What type of study is this?
It is a preclinical (animal / model) study, published in Journal of Medicinal Chemistry in 2026. To investigate its in vivo behavior, radiolabeled [14C]-Xinyne was prepared using [14C]-KCN.
Where can I read the original paper?
The original is at the publisher via DOI 10.1021/acs.jmedchem.6c00338. PubMed ID: 42720493. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/synthesis-biological-evaluation-and-biodistribution-of-xinyne-a-novel-qu-c00338/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides